LONDON (Business Wire EON) December 14, 2007 -- Pharmaceutical Product Approval Trends 2007 - Key market benchmarks and strategic insights finds that among the 40 new pharmaceutical products given first approval in 2006, 11 new drugs are considered to have the potential to generate peak annual sales in excess of US$500 million.
The leading 2006 approved product by forecast sales in 2011 is Merck's Gardasil/ Silgard which is a human papillomavirus vaccine. Gardasil is forecast to surpass sales of US$3 billion in 2011. Among the other drugs predicted to reach peak global sales higher than US$500 million are Novartis' anti-hypertensive Exforge(TM), Johnson and Johnson's protease inhibitor Prezista(TM), Sanofi-Aventis' appetite suppressant Acomplia(TM) (rimonabant), and smoking-cessation aid Chantix(TM) (varenicline).
The study says that the leading companies by number of new drug approvals with significant market potential in 2006 were Pfizer, J&J, Merck and Novartis with two.
Gardasil/ Silgard (human papillomavirus vaccine) is a recombinant vaccine indicated for the prevention of cervical cancer caused by human papillomavirus (HPV) and first received approval in the US in June 2006 before receiving EU approval in September 2006. It generated global sales of US$235 million in 2006.
Steven Seget, author of the report from URCH, commenting on the changes that have taken place in 2007, said, "The leading companies by current and prospective new pharmaceutical product approvals this year are GSK, Wyeth and Novartis with four potential approvals each." He notes that smaller companies are forecast to generate a high share of new drug approvals in 2007, including Shire with three and Cephalon with two.
For more information about Pharmaceutical Product Approval Trends 2007
URCH Publishing is an independent business information publisher dedicated to delivering high quality information products to the global pharmaceuticals industry.
Biotech Crops Experience Remarkable Dozen Years of Double-Digit Growth Socio-economic Benefits Becoming Evident Among Resource-Poor Farmers
After a dozen years of commercialization, biotech crops are still gaining ground with another year of double-digit growth and new countries joining the list of supporters, according to a report released today by the International Service for the Acquisition of Agri-biotech Applications (ISAAA). In 2007, biotech crop area grew 12 percent or 30.3 million acres to reach 282.3 million acres, the second highest area increase in the past five years.
Noni Maui, a Division of Noni Biotech International Becomes Official Supplier of University of Hawaii Cancer Research Center NIH Funded Human Trial
A new International Hawaiian Noni Biotech Company has recently announced that it is the official supplier of dehydrated Noni capsules to the University of Hawaii's Cancer Research Center's human trials. A study funded by the NIH and under the direction of Dr. Brian Issell MD, Oncologist and Director of the U of H Cancer Research Center, will attempt to establish the efficacy of using Noni capsules for treating cancer patients. Phase I will attempt to establish the proper Hawaiian Noni capsule dosage that will affect the patients quality of life, reduce pain levels and assist with defense of cancer growth.
Scientists from the Pharmaceutical Company GlaxoSmithKline and a Team of Academic, Biotech and Pharma Collaborators Released "microRNA: Biology,
"microRNA: Biology, Function & Expression" (ISBN: 1933255196) by Neil J. Clarke, PhD and Philippe Sanseau, PhD, scientists at GlaxoSmithKline, and a team of academic, pharma, and biotech collaborators has been just published by DNA PRESS.
Providing a comprehensive overview of a fast-emerging field, this volume dedicated to the biological role of microRNAs (miRNAs) discusses methods for identifying and characterizing their functions and looks at potential applications of miRNA research in medicine and pharmacology. MicroRNAs (miRNAs) are small, noncoding RNA molecules that appear to regulate gene expression. Found in plant and animal species and possibly traceable back to ancient forms of life, miRNAs are now estimated to regu...
The MedZilla Report: February Employment Outlook for Biotech/Pharma/Health
According to The MedZilla Report: February Employment Outlook for Biotech/Pharma/Health, while millions of people bemoan the financial market and their job prospects, those in the medical field continue to be in an enviable position: members of a profession whose positions have grown since the start of 2008.
